

NEW ZOMETA® AGREEMENT FROM NOVARTIS



Oncology Associates is pleased to announce a new agreement for ZOMETA® (zoledronic acid), effective January 1, 2005.

ZOMETA® is offered to all OA members in good standing at a significant **discount of 4%**. The product is available in 4mg/5mL vials.

ZOMETA® Injection is indicated for the treatment of hypercalcemia of malignancy. ZOMETA® is also indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.

Contact Oncology Associates at **888-732-7352** with any questions about the Novartis agreement. For more information about ZOMETA®, visit www.zometa.com.

PRODUCT NAME	STRENGTH	NDC#	VIALS/PKG	% DISCOUNT
Zometa®	4 mg/5 mL vial	0078-0387-25	1	4%

SANDOSTATIN LAR® REBATES RELEASED



As part of the OA product agreement with Novartis for Sandostatin LAR®, we are pleased to announce the release of August and September 2004 rebate checks. Eligible members should have already received these checks, as they were issued on December 2, 2004 (August) and December 27, 2004 (September).

October rebates were released March 2, 2005 and as a reminder, eligible members can look forward to November and December rebates to be released sometime this year.

Rebates are earned on a monthly basis with the resulting checks sent to the practice at approximately 90 days from the end of each month.

Contact Oncology Associates at 888-732-7352 with any questions regarding the rebates earned.

VIDAZA AND INNOHEP AGREEMENT REMINDER



Oncology Associates would like to remind you of its agreement with Pharmion for Vidaza (azacitidine for injectable suspension). This product is available to all OA Members in good standing.

Vidaza is available in 100 mg vials and is indicated for the treatment of all five Myelodysplastic Syndrome (MDS) subtypes.

These subtypes include:

- > Refractory anemia (RA)
- > Refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions)
- > Refractory anemia with excess blasts (RAEB)
- > Refractory anemia with excess blasts in transformation (RAEB-T)
- > Chronic myelomonocytic leukemia (CMML)

Innohep Agreement Reminder



Oncology Associates would also like to remind you of its contract for Innohep® (tinzaparin sodium for injection) with Pharmion Corporation. Innohep® is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin®).

Innohep® is currently available through FloridaInfusion Services. Contact FIS directly at **800-624-0152** to place an order.

For more information on Vidaza and Innohep, visit Pharmion's website at pharmion.com or contact Pharmion directly for complete prescribing information at **1-866-PHARMION**. Please call Oncology Associates at **888-732-7352** with any questions regarding these agreements.

NDC#	PRODUCT NAME	STRENGTH	PACKAGE SIZE
67211-342-08	Innohep® (tinzaparin sodium for injection)	20,000 IU/mL	2mL vial
67211-342-53	Innohep® (tinzaparin sodium for injection)	20,000 IU/mL	10 x 2mL vial
67211-102-01	Vidaza (azacitidine for injectable suspension)	100 mg	100 mg/vial